Glaxo Diabetes Drug Approved As First-Line Treatment
Posted on: Tuesday, 11 July 2006, 15:00 CDT
GlaxoSmithKline's diabetes drug Avandamet has been approved by the FDA for use as a first-line treatment of type 2 diabetes as an adjunct to diet and exercise.
Avandamet, a combination of GSK's Avandia (rosiglitazone maleate) and the diabetes drug metformin, was previously only approved as second-line therapy for patients who were uncontrolled on metformin monotherapy.
"Rosiglitazone targets insulin resistance, an underlying cause of type 2 diabetes, whereas metformin primarily works to reduce the amount of blood sugar (or glucose) produced by the liver. In fact, a clinical trial comparing Avandamet to both rosiglitazone alone and metformin alone showed that patients taking Avandamet achieved significantly lower blood sugar levels than with either monotherapy alone," said Dr Barry Goldstein, director of the division of endocrinology, diabetes and metabolic diseases at Jefferson Medical College of Thomas Jefferson University, Philadelphia.
Type 2 diabetes is characterized by high blood sugar levels that occur when the body does not produce enough insulin or does not respond properly to its own natural insulin, a condition called insulin resistance.
Source: Datamonitor
Related Articles
- Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization
- One-Year Data Showed Investigational Use of Initial Combination Therapy With JANUVIA(TM) (Sitagliptin) and Metformin Significantly Improved Blood Sugar Control in Patients With Type 2 Diabetes Compared to Metformin Alone
- Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects With Type 2 Diabetes Compared to Metformin Alone
- New Study Demonstrates Colesevelam HCl Lowers Both A1C And LDL Cholesterol in Patients With Uncontrolled Type 2 Diabetes Mellitus on Metformin-Based Regimen
- Oral Insulin Tested for Type 1 Diabetes
- CVAC Systems and TempusClinic Partner to Study the Potential Value of The CVAC Process in Managing and Treating Diabetes, Insulin Resistance, and Metabolic Syndrome
- Insulin Resistance and Type 2 Diabetes in High-Fat-Fed Mice Are Linked to High Glycotoxin Intake
- Effects of Metformin and Rosiglitazone Treatment on Insulin Signaling and Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Study
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea
- Subcellular Localization of ALMS1 Supports Involvement of Centrosome and Basal Body Dysfunction in the Pathogenesis of Obesity, Insulin Resistance, and Type 2 Diabetes
 |
 |
User Comments (0)
RSS Feeds